WO2004065351A1 - Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 - Google Patents
Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 Download PDFInfo
- Publication number
- WO2004065351A1 WO2004065351A1 PCT/EP2004/000571 EP2004000571W WO2004065351A1 WO 2004065351 A1 WO2004065351 A1 WO 2004065351A1 EP 2004000571 W EP2004000571 W EP 2004000571W WO 2004065351 A1 WO2004065351 A1 WO 2004065351A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- hydrogen
- aralkyl
- heteroaralkyl
- alkyl
- Prior art date
Links
- 0 C*(CCC(C)(*)CC1CCC2)CC1*2C(c1ccc(*(CC2)N)c2c1*)=O Chemical compound C*(CCC(C)(*)CC1CCC2)CC1*2C(c1ccc(*(CC2)N)c2c1*)=O 0.000 description 5
- VILBQMFLIPXICN-PBVYKCSPSA-N COc1ccccc1C(Nc1cc(C(N2C(CCCC3)[C@@H]3CCC2)=O)ccc1)=O Chemical compound COc1ccccc1C(Nc1cc(C(N2C(CCCC3)[C@@H]3CCC2)=O)ccc1)=O VILBQMFLIPXICN-PBVYKCSPSA-N 0.000 description 1
- GSNZVAQTIZZAHQ-RHSMWYFYSA-N C[n](c(C(N1[C@H](CCCC2)[C@H]2CCC1)=O)c1)c2c1cccc2 Chemical compound C[n](c(C(N1[C@H](CCCC2)[C@H]2CCC1)=O)c1)c2c1cccc2 GSNZVAQTIZZAHQ-RHSMWYFYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- the present invention provides amide derivatives of the formula
- R , and R 2 are independently hydrogen, cyano, halo, nitro, trifluoromethyl, optionally substituted amino, alkyl, alkoxy, aryl, aralkyl, heteroaryl or heteroaralkyl; or
- Ri and R 2 combined together with the carbon atoms they are attached to form an optionally substituted 5- to 7-membered aromatic or heteroaromatic ring;
- R 3 is optionally substituted lower alkyl
- R 3 and R 2 combined together with the amide group to which R 3 is attached and the carbon atoms to which R 2 and the amide are attached form an optionally substituted 5- to 7-membered carbocyclic or heterocyclic ring;
- R 4 is optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaralkyl; or
- R 4 and R 3 taken together with the nitrogen atom to which they are attached form a.,5-- to 8-membered ring which may be optionally substituted or may contain another heteroatom selected from oxygen, nitrogen and sulfur; or
- R 4 and R 3 taken together with the nitrogen atom to which they are attached form a 8- to 12-membered fused bicyclic ring, which may be optionally substituted or may contain another heteroatom selected from oxygen, nitrogen and sulfur;
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6> -NR 5 C(O)NR 6 R > -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6) -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R in which
- R 5 and R 7 are independently hydrogen, optionally substituted alkyl or aralkyl; or
- R 5 and R-* are optionally substituted alkylene which combined together with the nitrogen atom to which R 5 is attached and the carbon atoms to which W and R-, are attached form a 5- or 6-membered ring;
- R 6 is optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaralkyl
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, cycloalkyl, heterocyclyl, heterocyclo- alKyl, aralkyl, heteroaralkyl, alkanoyl, aroyl or heteroaroyl; or
- W is aryl or heteroaryl
- W is hydrogen provided that R . is -NR 5 Z in which Z is -C(O)R 6 , -C(O)OR 6 , -C(O)NR 6 R 7l -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ; or
- W and R combined together with the carbon atoms to which they are attached form a 6-membered aromatic or heteroaromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 ;
- X and Y are independently CH or nitrogen; or
- the compounds of the present invention provide pharmacological agents which may be employed to control local tissue concentrations of hormonally active glucocorticoids in mammals, in particular cortisol levels in humans and, therefore, may be employed for the treatment of disorders associated with elevated glucocorticoid concentrations.
- the compounds of the invention are inhibitors of 11 ⁇ -hydroxysteroid dehydrogenase4ype ⁇ 1- (11 ⁇ - HSD1) reductase activity.
- the bidirectional 11 ⁇ -HSD1 enzyme acts in vivo predominantly as oxoreductase converting hormonally inactive glucocorticoids to their active * 1 ⁇ -hydroxy metabolites.
- the compounds of the invention lower intracellular glucocorticoid concentrations in mammals, in particular intracellular cortisol levels in humans, improving insulin sensitivity in the muscle and the adipose tissue. Furthermore, by lowering intracellular glucocorticoid concentrations in mammals, the compounds of the instant invention reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention also lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. The compounds of the instant invention are thus particularly useful.
- the compounds of the invention may also be employed to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity.
- the invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful forthe treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.
- Selective 11 ⁇ -HSD1 inhibitors of the instant invention which are substantially free of undesirable side effects resulting from the inhibition of other hydroxysteroid dehydrogenases are preferred.
- the present invention relates to the modulation of local tissue concentrations of hormonally active glucocorticoids, to methods by which the level of glucocorticoids may be controlled, and to useful therapeutic effects which may be obtained, as a result of such control.
- the invention is concerned with the reduction of cortisol levels in humans.
- the present invention is directed to amide derivatives of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds for the treatment of disorders " associated with elevated glucocorticoid concentrations, such as type-2 diabetes, Syndrome-X, dyslipidemia, hypertension and central obesity.
- optionally substituted alkyl refers to unsubstituted or substituted "" straightpr, branched chain hydrocarbon groups having 1 to 20 carbon atoms, preferably 1 to 7 carbon atoms.
- exemplary unsubstituted alkyl groups include methyl, ethyl, propyl, isopropyl, t.-butyl, t-buiy ⁇ , isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpenthyl, octyl and the like.
- Substituted alkyl groups include, but are not limited to, alkyl groups substituted by one or more of the following groups: halo, hydroxy, cycloalkyl, alkanoyl, alkoxy, alkyloxyalkoxy, alkanoyloxy, amino, alkylamino, dialkylamino, alkahoylamino, thiol, alkylthio, alkylthiono, alkylsulfonyl, arylsulfonyl, heteroaryls ⁇ lfonyl, sulfonamido, nitro, cyano, carboxy, alkoxycarbonyl, aryl, aralkoxy, guanidino, heterocyclyl including indolyl, imidazolyl, furyl, tfiienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, piperidyl, morpholinyl and the
- lower alkyl refers to those alkyl groups as described above having 1 to 7, preferably 1 to 4 carbon atoms.
- halogen or “halo” refers to fluorine, chlorine, bromine and iodine.
- alkenyl refers to any of the above alkyl groups having at least 2 carbon atoms and a carbon to carbon double bond at the point of attachment. Groups having two to four carbon atoms are preferred.
- alkynyl refers to any of the above alkyl groups having at least two carbon atoms and a carbon to carbon triple bond at the point of attachment. Groups having two to four carbon atoms are preferred.
- alkylene refers to a straight chain bridge of 1 to 6 carbon atoms connected by single bonds ⁇ (e.g., -(CH 2 ) ⁇ - wherein x is 1 to 6), which may be substituted with 1 to 3 lower alkyl groups.
- cycloalkyl refers to optionally substituted monocyclic, bicyclic or tricyclic hydrocarbon groups of 3 to 10 carbon atoms, each of which may optionally be substituted by one or more substituents such as alkyl, halo, oxo, hydroxy, alkoxy, alkanoyl, amino, alkylamino, dialkylamino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkyl- and arylsulfonyl, sulfonamido, heterocyclyl and the like.
- substituents such as alkyl, halo, oxo, hydroxy, alkoxy, alkanoyl, amino, alkylamino, dialkylamino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkyl- and arylsulfony
- Exemplary monocyclic hydrocarbon groups include but are not limited to cyclopropyl, ⁇ yclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl and the like.
- bicyclic hydrocarbon groups include bornyl, indyl, hexahydroindyl ? tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like.
- Exemplary tricyclic hydrocarbon groups include adamantyl and the like.
- alkoxy refers to alkyl-O-.
- acyl refers to alkanoyl, aroyl, heteroaroyl, arylalkanoyl or heteroarylalkanoyl.
- alkanoyl refers to alkyl-C(O)-.
- alkanoyloxy refers to alkyl-C(O)-O-.
- alkylamino and dialkylamino refer to alkyl-NH- and (alkyl),N-, respectively.
- alkanoylamino refers to alkyl-C(O)-NH-.
- alkylthio refers to alkyl-S-.
- alkylaminothiocarbonyl refers to alkyl-NHC(S)-.
- alkylthiono refers to alkyl-S(O)-.
- alkylsulfonyl refers to alkyl-S(O) 2 -.
- alkoxycarbonyl refers to alkyl-O-C(O)-.
- alkoxycarbonyloxy refers to alkyl-O-C(O)O-.
- carbamoyl refers to alkyl-NH-C(O)-, (alkyl) 2 N-C(O)-, aryl-NHC(O)-, alkyl(aryl)-N- C(O)-, heteroaryl-NH-C(O)-, alkyl(heteroaryl)-N-C(O)-, aralkyl-NH-C(O)- and alkyl(araikyl)-N- C(O)-.
- optionally substituted amino refers to a primary or secondary amino group which may optionally be substituted by a substituent such as acyl, alkylsulfonyl, aryl- and heteroarylsulfonyl, aralkyl- and heteroaralkylsulfonyl, alkoxy- and cycloalkpxycarb ⁇ nyl, aryloxy- and heteroaryloxycarbonyl, aralkoxy- and heteroaralkoxycarbonyl, carbamoyl, alkyl- and arylaminothiocarbonyl and the like.
- a substituent such as acyl, alkylsulfonyl, aryl- and heteroarylsulfonyl, aralkyl- and heteroaralkylsulfonyl, alkoxy- and cycloalkpxycarb ⁇ nyl, aryloxy- and heteroaryloxycarbonyl, aralkoxy- and heteroaralkoxy
- aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, tetrahydronaphthyl, biphenyl and diphenyl groups, each of which may optionally be substituted by one to four substituents such as alkyl, halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, optionally substituted amino, thiol, alkylthio, nitro, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, alkylthiono, alkyl- and arylsulfonyl, sulfonamido, heterocycloyl and the like.
- monocyclic aryl refers to optionally substituted phenyl as described under aryl.
- aralkyl refers to an aryl group bonded directly through an alkyl group, such as benzyl.
- aralkoxy refers to an aryl group bonded directly through an alkoxy group.
- arylsulfonyl refers to aryl-S(O) 2 -.
- aroyl refers to aryl-C(O)-.
- aroylamino refers to aryl-C(O)-NH-.
- aryloxycarbonyl refers to aryl-O-C(O)-.
- heterocyclyl refers to an optionally substituted, fully saturated or unsaturated, aromatic or nonaromatic cyclic group, for example, which is a 4- to 7- membered monocyclic, 7- to 12-membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring.
- Each ring of the heterocyclic group containing a heteroatom may have 1 , 2 or 3 heteroatoms selected frpm nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized.
- the heterocyclic group may be attached at a heteroatom or a carbon atom.
- Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyrid
- bicyclic heterocyclic groups include indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, tetrahydroquinolinyl, decahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]-pyridinyl] or furo[2,3- b]pyridinyl), dihydroisoindolyl, dihydroquinazolin
- heterocyclyl includes substituted heterocyclic groups.
- Substituted heterocyclic groups refer to heterocyclic groups substituted with 1 , 2 or 3 substitutents selected from the group consisting of the following:
- alkoxycarbonyl such as unsubstituted lower alkoxycarbonyl
- heterocyclooxy denotes a heterocyclic group bonded through an oxygen bridge.
- heteroaryl refers to an aromatic heterocycle, for example monocyclic or bicyclic aryl, such as pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzofuryl, and the like, optionally 'substituted by, e.g., lower alkyl, lower alkoxy or halo.
- heteroarylsulfonyl refers to heteroaryl-S(O) 2 -.
- heteroaroyl refers to heteroaroyl-C(O)-.
- heteroarylkyl refer to a heteroaryl group bonded through an alkyl group.
- prodrug derivatives e.g., any pharmaceutically acceptable prodrug ester derivatives of the carboxylic acids of the invention which are convertible, by solvolysis or under physiological conditions to the free carboxylic acids.
- carboxylic acid esters are preferably lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono or disubstituted lower alkyl esters, e.g., the ⁇ - (amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the ⁇ -(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as the pivaloyloxy-methyl ester, and the like conventionally used in the art.
- the compounds of the invention depending on the nature of the substituents, may possess Qne or more asymmetric centers.
- the resulting diastereoisomers, enantiomers ⁇ ahd * geometric isomers are encompassed by the instant invention.
- R-i and R 2 are independently hydrogen, halo, optionally substituted amino, lower alkyl or lower alkoxy; or
- R* ⁇ and R 2 combined together with the carbon atoms they are attached to form an optionally substituted 6-membered aromatic ring;
- R 3 is lower alkyl
- R 3 and R 2 combined together with the amide group to which R 3 is attached and the carbon atoms to which R 2 and the amide are attached form an optionally substituted 5- to 7-membered carbocyclic or heterocyclic ring;
- R 4 is optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaralkyl; or R 4 and R 3 taken together with the nitrogen atom to which they are attached form a fully saturated optionally substituted 6-membered ring; or
- R 3 taken together with the nitrogen atom to which they are attached form a fully saturated 10-mernbered fused bicyclic ring, which may be optionally substituted or may contain another heteroatom selected from oxygen, nitrogen and sulfur;
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or lower alkyl; or 3 and R . are optionally substituted alkylene which combined together with the nitrogen atom to which R 5 is attached and the carbon atoms to which W and R-i are attached form a 5-membered ring;
- R 6 is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; or
- W is aryl or heteroaryl
- W is hydrogen provided that R-, is -NR 5 Z in which Z is -C(O)R 6 , -C(O)OR 6 , -C( ⁇ )NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ; or
- W and R-i combined together with the carbon atoms to which they are attached form a 6-membered aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 ;
- X and Y are independently CH or nitrogen; or
- R . and R 2 are independently hydrogen, halo, optionally substituted amino, lower alkyl or lower alkoxy; or
- R. and R 2 combined together with the carbon atoms they are attached to form an optionally substituted 6-membered aromatic ring;
- R 3 is methyl or ethyl; or
- R 3 and R 2 combined together with the amide group to which R 3 is attached and the carbon atoms to which R 2 and the amide are attached form a 5- to 7-membered carbocyclic ring;
- R 4 is -(CHR* ⁇ ) n Ri2 in which n is zero or an integer from 1 to 3;
- Rn is hydrogen, hydroxy or optionally substituted lower alkyl
- R- I2 is aryl, heterocyclyl or cycloalkyl
- R 4 and R 3 taken together with the nitrogen atom to which they are attached form an optionally substituted decahydroquinoline or decahydroisoquinoline which may contain another heteroatom selected from oxygen, nitrogen and sulfur;
- W is - R 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 5 and Ri are alkylene which combined together with the nitrogen atom to which R 5 is attached and the carbon atoms to which W and R-* are attached form a 5- membered ring;
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R g is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; or
- W is optionally substituted aryl or heteroaryl
- W is hydrogen provided that R-, is -NR 5 Z in which Z is -C(O)R 6 , -C(O)OR 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ; or
- W and R combined together with the carbon atoms to which they are attached form a 6-membered aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 ;
- X is CH
- R , and R 2 are independently hydrogen, halo, lower alkyl* or lower alkoxy; or
- R-i and R 2 combined together with the carbon atoms they are attached to form an optionally substituted 6-membered aromatic ring;
- R 3 is methyl or ethyl
- R 4 is -(CHRn) n R 12 in which ⁇ is zero or an integer of 1 ; t
- Rn is hydrogen
- R 12 is optionally substituted cyclohexyl; or R 12 is optionally substituted 1 -adamantyl providing that n is an integer of 1;
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or 1 heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; or
- W is aryl or heteroaryl
- W and Ri combined together with the carbon atoms to which they are attached form a 6-membered aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 ;
- X is CH
- Y is CH or nitrogen
- R 10 is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.
- Preferred are the compounds in the B group wherein ' Ri is hydrogen;
- R 2 is hydrogen, chloro or methoxy;
- R 3 is methyl;
- R 4 is -(CHR* ⁇ ) n Ri2 in which n is zero or an integer of 1 ;
- Rn is hydrogen
- R ⁇ is optionally substituted cyclohexyl; or R 12 is optionally substituted 1- adamantyl providing that n is an integer of 1 ;
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl;
- X is CH
- Y is CH; or a pharmaceutically acceptable salt thereof.
- R- t is hydgogen
- R 2 is hydrogen or methyl
- R 3 is methyl
- R 4 is -(CHR* ⁇ ) n Ri2 in which n is an integer of 1 ;
- Rn is hydrogen
- R 12 is optionally substituted 1 -adamantyl; W is optionally substituted aryl or heteroaryl; or
- W and Ri combined together with the carbon atoms to which they are attached form a 6-membered aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl
- Z is -C(O)R 6 , -C(O)O,R 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 in which
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R . and R 2 are independently hydrogen, halo, optionally substituted amino, lower alkyl or lower alkoxy; or
- R, and R 2 combined together with the carbon atoms to which they are attached form an optionally substituted 6-membered aromatic ring;
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR,5R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 5 and R-* are alkylene which combined together with the nitrogen atom to which R 5 is attached and the carbon atoms to which W and R. are attached form a 5- membered ring;
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; or
- W is aryl or heteroaryl
- W is hydrogen provided that R. is -NR 5 Z in which Z is -C(O)R 6 , -C(O)OR 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ; or
- W and R-i combined together with the carbon atoms they are attached to form a 6-membered'aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(0)NR 6 R 7 , -ORg or -OC(O)NR 6 R 7 ;
- X is CH
- Y is CH or nitrogen
- R 13 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- the compounds of formula (la) in the C group may contain the decahydroquinoline noiety either in the trans or the cis configuration, or a mixture of trans and cis isomers thereof. Any optical isomer or a mixture of optical isomers thereof are also encompassed-by the present invention.
- R-i is hydrogen
- R 2 is hydrogen, chloro, methoxy, ethoxy, propoxy or optionally substituted amino
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl
- X is CH
- Y is CH;
- R 13 and R 1 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- Ri is methyl, methoxy or optionally substituted amino
- R 2 is hydrogen
- W is -N [ R 5 C(O)R 6 , -NR 5 C(O)OR 6> -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O ⁇ NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; X is CH; Y is CH;
- R 13 and R 4 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- R-i and R 2 are hydrogen
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl
- X is CH;
- Y is nitrogen
- Ri3 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- W is hydrogen
- R 2 is hydrogen
- R. is -N
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- X is CH
- Y is CH
- R 1 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR5R- 3 , -C(O)NR 6 R 7 , -ORg or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl;
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R g is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl;
- Y is CH
- R- I 3 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- R 2 is hydrogen, halo or alkoxy
- Y is CH or nitrogen
- R 13 and R u are independently hydrogen, hydroxy or optionally substituted loweralkyl
- R 15 is hydrogen, -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R6, -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; or a pharmaceutically acceptable salt thereof.
- Preferred in the C group are also the compounds of the formula
- R 2 is hydrogen
- Z is -C(O)R 6 , -C(O)OR 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 in which
- Re is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or hetproaralkyl;
- R 7 is hydrogen or methyl
- R 8 is hydrogen, optiorially substituted alkyl, aralkyl or heteroaralkyl
- Y is CH
- R 1 3 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- Ri and R are independently hydrogen, halo or lower alkyl
- W is aryl or heteroaryl
- W and R-i combined together with the carbon atoms to which they are attached form a 6-membered aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- Z is -C(O)R ⁇ , -C(O)OR 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ;
- R 5 and R 7 are independently hydrogen or methyl;
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- Rs is optionally substituted alkyl, aralkyl or heteroaralkyl
- Rg is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl
- R 13 and R M are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- R 2 is hydrogen, halo or lower alkyl
- R 1 3 and R 1 are independently hydrogen, hydroxy or optionally substituted lower alkyl
- Ri 6 is hydrogen, halo, alkyl, aryl, heteroaryl or -NR 5 Z in which
- Z is -C(O)R 6 , -C(O)OR 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ;
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl; or a pharmaceutically acceptable salt thereof.
- R 2 is hydrogen, halo or lower alkyl
- R 1 0 is hydrogen or methyl
- R 13 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl
- R 16 is hydrogen, halo, alkyl, aryl, heteroaryl or -NR 5 Z in which
- Z is -C(O)R ⁇ , -C(O)OR ⁇ , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ;
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl; or a pharmaceutically acceptable salt thereof.
- R 2 are independently hydrogen, halo, optionally substituted amino, lower alkyl or lower alkoxy; or
- R-i and R 2 combined together form an optionally substituted 6-membered aromatic ring
- W is -NR 5 C(O)R 6 , -NR 5 C(O)ORe, -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 5 and R-i are alkylene which combined, together with the nitrogen atom to which R 5 is attached and the carbon atoms to which W and R . are attached form a 5- membered ring;
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; or W is aryl or heteroaryl; or
- W and Ri combined together with the carbon atoms to which they are attached form a 6-membered aromatic ring optionally substituted with alkyl, alkoxy, aryl, heteroaryl, halo, -NR 5 Z, -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- Z is -C(O)R 6 , -C(O)OR ⁇ , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 ;
- R 13 and R 1 are independently hydrogen, hydroxy or optionally substituted lower alkyl
- X is CH
- Y is CH or nitrogen
- the compounds of formula (Ih) in the D group may contain the decahydroisoquinoline moiety either in the trans or the cis configuration. Any optical isomer or a mixture of optical isomers thereof are also encompassed by the present invention.
- R 2 is hydrogen, chloro, methoxy, ethoxy, propoxy or optionally substituted amino
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -Np5S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl
- X is CH
- Y is CH
- R*i3 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof. Preferred are also the compounds of formula (Ih) wherein
- R t is methyl, methoxy or optionally substituted amino
- R is hydrogen
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl
- X is CH
- Y is CH
- R 13 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- R-i and R 2 are hydrogen
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NRgS(O) 2 R 6 -NR 5 R- 3 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl; t- X is CH;
- Y is nitrogen
- R 13 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- Preferred in the D group are also the compounds of the formula
- W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6> -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or hetejr ⁇ aralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- ⁇ Rg is hydrogen, optionally substituted alkyl, aralkyl, heteroaralkyl or alkanoyl;
- Y is CH
- R 13 and R 14 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- R 2 is hydrogen
- Z is -C(O)R 6 , -C(O)OR 6 , -C(O)NR 6 R 7 , -C(S)NR 6 R 7 , -S(O) 2 R 6 , or -R 8 in which
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 7 is hydrogen or methyl ' ;
- R 8 is hydrogen, optionally substituted alkyl, aralkyl or heteroaralkyl
- Y is CH; R- 1 3 and R 1 are independently hydrogen, hydroxy or optionally substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
- R . is hydrpgen
- R 4 is -(CHRn) n Ri2 in which n is zero or an integer from 1 to 2;
- .Rn is hydrogen
- R 12 is aryl, heteroaryl, heterocyclyl or cycloalkyl
- W is -NR 5 C(O)R e , -NR 5 C(O)OR 6 , -NR 5 C(O)NR 6 R 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 , -NR 5 R 8 , -C(O)NR 6 R 7 , -OR 9 or -OC(O)NR 6 R 7 in which
- R 5 and R 7 are independently hydrogen or methyl
- R 6 is optionally substituted alkyl, aryl, hetroaryl, cycloalkyl, aralkyl or heteroaralkyl;
- R 8 is optionally substituted alkyl, aralkyl or heteroaralkyl
- R 9 is (C 1 . 6 )alkyl substituted by cycloalkyl, alkoxy, cycloalkoxy, alkylthio, aryloxy, heterocyclooxy, arylthio, aryl or heteroaryl;
- Y is CH; m is zero or an integer from 1 to 2; or a pharmaceutically acceptable salt thereof.
- salts of any acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris-(hydroxymethyl)- methylammonium salts.
- bases namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris-(hydroxymethyl)- methylammonium salts.
- acid addition salts such as of mineral acids, organic carboxylic, and organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid
- a basic group such as pyridyl
- W represents W as defined herein, or vy is a group convertible to W, with an amine or an acid addition salt thereof of the formula
- R has meaning as defined herein, R 3 ' represents R 3 as defined herein, or R 3 ' is a group convertible to R 3 , to form a compound of the formula
- R*-, R 2 , R 4 , X and Y have meaning as defined herein
- R 3 ' and W represent R 3 and W as defined herein, or R 3 ' and W are groups convertible to R 3 and W, respectively.
- Carboxylic acids of formula (II) and amines of formula (III) may be prepared using methods described herein or modifications thereof or using methods well known in the art.
- activated derivatives of carboxylic acids include acid chlorides, bromides and fluorides, mixed anhydrides, lower alkyl esters, and activated esters thereof, and adducts formed with coupling agents such as 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride, O-(1 ,2-dihydro-2-oxo-1-pyridyl)-/V, ⁇ /, ⁇ /', ⁇ /'- tetramethyluronium tetrafluoroborate and the like.
- coupling agents such as 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride, O-(1 ,2-dihydro-2-oxo-1-pyridyl)-/V, ⁇ /, ⁇ /', ⁇ /'- tetramethyluronium tetrafluoroborate and the like.
- Mixed anhydrides are preferably such from pivalic acid, or lower alkyl hemiesters of carbonic acids, such as ethyl or isobutyl analogs.
- Activated esters include, for example, succinimido, phthalimido or 4-nitrophenyl esters.
- reaction of an activated derivative of a carboxylic acid, e.g., those of formula (II), with an amine, e.g., those of formula (III), may be carried out in the presence of a base such as triethylamine, dusopropylethylamine or ⁇ /-methylmorpholine in an inert solvent such as dtchloromethane, ⁇ /, ⁇ /-dimethylformamide or tetrahydrofuran.
- Carboxylic acids of formula (II) can be converted to their activated derivatives using methods described herein or modifications thereof or using methods well known in the art.
- Groups convertible to W include nitro, trifuoromethylsulfonate, bromine and chlorine.
- compounds of formula (I') in which W is nitro can be first reduced to the corresponding amines of the formula
- R**, R 2 , R 4 , X and Y have .meaning as defined herein, and R 3 ' represents R 3 , according to methods well described in the art, e.g., with hydrogen in the presence of a catalyst such as palladium on carbon in a polar solvent such as ethyl acetate, methanol or ethanol.
- a catalyst such as palladium on carbon in a polar solvent such as ethyl acetate, methanol or ethanol.
- Compounds of formula (I') wherein R t , R 2 , R 3 ⁇ R , X and Y have meaning as defined herein and W is nitro may be prepared as described herein or modifications thereof, or using methods well known in the art.
- compounds of formula (IV) in which R 1 ( R 2 , R 4 , X and Y have meaning as defined herein, and R 3 ' represents R 3 may be prepared by reacting compounds of formula (I') wherein W is trifuoromethanesulfonate, bromine or chlorine and R 1 ( R , R 4 , X and Y have meaning as defined herein, and R 3 ' represents R 3 , with benzophenone imine under conditions of a Buchwald condensation or using other methods well known in the art.
- Compounds of formula (IV) can then be treated with a /V-derivatizing agent, such as an activated derivative of a carboxylic acid, a chloroformate, a sulfonyl chloride, an isocyanate or a thioisocyanate to obtain compounds of formula (I') in wherein R-i, R , R 4 , X and Y have meanings as defined herein, and R 3 ' represents R 3 , and W is -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -NR 5 C(O)NReR 7 , -NR 5 C(S)NR 6 R 7 , -NR 5 S(O) 2 R 6 in which R 5 , R 6 and R 7 have meanings as defined herein.
- a /V-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate, a sulfonyl chloride, an isocyan
- the reaction to form compounds of formula (I') may be carried out under an inert atmosphere, in the presence of a base such as triethylamine, dusopropylethylamine or ⁇ /-methylmorpholine in an inert solvent or a mixture of solvents such as acetonitrile, dtchloromethane, N, ⁇ /-dimethylformarnide or tetrahydrofuran.
- a base such as triethylamine, dusopropylethylamine or ⁇ /-methylmorpholine
- solvents such as acetonitrile, dtchloromethane, N, ⁇ /-dimethylformarnide or tetrahydrofuran.
- R*-, R 2 , R 3 , R 4 , X and Y have meaning as defined herein, with an amine or an acid addition salt thereof of the formula
- Carboxylic acids of formula (V) t and amines of formula (Vi) may be prepared according to methods described herein or modifications thereof, or using methods well known in the art.
- compounds of formula (I') wherein W is hydroxy may be treated with alcohols of formula RgOH under Mitsunobu conditions, e.g., in the presence of triphenylphoshine and diethyl azodicarboxylate in an organic solvent such as tetrahydrofuran, to afford compounds of formula (I').
- protecting groups are to protect the functional groups from undesired reactions with reaction components under the conditions used for carrying out a desired chemical transformation.
- the need and choice of protecting groups for a particular reaction is known to those skilled in the art and depends on the nature of the functional group to be protected (hydroxy group, amino group, etc.), the structure and stability of the molecule of which the substituent is a part and the reaction conditions.
- the above-mentioned reactions are carried out according to standard methods, in the presence or absence of diluent, preferably such as are inert to the reagents and are solvents thereof, of catalysts, condensing or said other agents respectively and/or inert atmospheres, , at low temperatures, room temperature or elevated temperatures (preferably at or near the boiling point of the solvents used), and at atmospheric or super-atmospheric pressure.
- diluent preferably such as are inert to the reagents and are solvents thereof, of catalysts, condensing or said other agents respectively and/or inert atmospheres, , at low temperatures, room temperature or elevated temperatures (preferably at or near the boiling point of the solvents used), and at atmospheric or super-atmospheric pressure.
- the invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, " or in which the reaction components are used in the form of their salts or optically pure antipodes.
- the invention also relates to any novel starting materials and processes for their manufacture.
- the new compounds may be in the form of one of the possible isomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, optical isomers (antipodes), racemates, or mixtures thereof.
- the aforesaid possible isomers or mixtures thereof are within the purview of this invention.
- Any resulting mixtures of isomers can be separated on the basis of the physico-chemical differences of the constituents, into the pure geometric or optical isomers, diastereoisomers, racemates, for example by chromatography and/or fractional crystallization.
- Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereoisomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
- the carboxylic acid intermediates can thus be resolved into their optical antipodes, e.g., by fractional crystallization of D- or L-(alpha-methylbenzylamine, cinchonidine, cinchonine, quinine, quinidine, ephedrine, dehydroabietylamine, brucine or s * frychnine)-salts.
- Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography using a chiral adsorbent.
- Acidic compounds of the invention may be converted into salts with pharmaceutically acceptable bases, e.g., an aqueous alkali metal hydroxide, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. From the solutions of the latter, the salts may be precipitated with ethers, e.g., diethyl ether. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained.
- bases e.g., an aqueous alkali metal hydroxide
- an ethereal or alcoholic solvent such as a lower alkanol.
- ethers e.g., diethyl ether
- Resulting salts may be converted into the free compounds by treatment with acids.
- Compounds of the invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acfd, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (C C 4 )-alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or gnsaturated dicarboxylic acids, for example, oxalic, succinic, maleic or fumaric acid s ⁇ bh as hydroxy-carboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (C t -C 4 )-alkyl-sulfonic acids (for example methanesulfonic acid) or arylsulf
- the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal and parenteral administration to mammals, including man, for the treatment of conditions associated with increased 11 ⁇ -HSD1 oxoreductase activity which can lead to elevated local tissue concentrations of hormonally active glucocorticoids, such as cortisol in man.
- Such conditions include Syndrome-X, dyslipidemia, hypertension, central obesity, and insulin resistance and hyperglycemia in Type 2 diabetes.
- the said pharmaceutical compositions comprise a therapeutically effective amount of a pharmacologically active compound of the instant invention, alone or in combination with another therapeutic agent and one or more pharmaceutically acceptable carriers.
- the pharmacologically active compounds of the invention may be employed in the manufacture of pharmaceutical compositions comprising a therapeutically effective amount r thereof in cqnjunction or admixture with excipients or carriers suitable for either enteral or parenteral application.
- Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, algin
- compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty" emulsions or suspensions.
- Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, sajts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.
- Suitable formulations for transdermal application include a therapeutically effective amount of a compound of the invention with carrier.
- Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- the pharmaceutical formulations contain a therapeutically effective amount of a compound of the invention as defined above, either alone or in a combination with another therapeutic a'gent, e.g., each at an effective therapeutic dose as reported in the art.
- Such therapeutic agents include insulin, insulin derivatives and mimetics; insulin secretagogues, such as the sulfonylureas, e.g., Glipizide, glyburide and Amaryl; insulinotropic sulfonylurea receptor ligands, such as meglitinides, e.g., nateglinide and repaglinide; PPAR ⁇ and/or PPAR ⁇ (peroxisome proliferator-activated receptor) ligands such as MCC-555, MK767, L-165041 , GW7282 or thiazolidinediones such as rosiglitazone, pioglitazone, troglitazone; insulin sensitizers, such as protein tyrosine phosphatase-1 B (PTP-1B) inhibitors such as PTP-112; GSK3 (glycogen synthase kinase-3) inhibitors such as SB-517955, SB-4195052, SB
- a compound of the present invention may be administered either simultaneously, before or after the other active ingredient, either separately by the same or different route of administration or together in the same pharmaceutical formulation.
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention in combination with one or more pharmaceutically acceptable carriers.
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention in combination with a therapeutically effective amount of another therapeutic agent, preferably selected from anti- diabetics, hypolipidemic agents, anti-obesity agents, anti-hypertensive agents or inotropic agents, most preferably from antidiabetics or hypolipidemic agents as described above.
- a pharmaceutical composition as described above for use as a medicament for use as a medicament.
- a pharmaceutical composition or combination as described above for the preparation of a medicament for the treatment of conditions associated with 11 ⁇ -HSD1 oxoreductase activity preferably, impaired glucose tolerance, Type 1 or Type 2 diabetes, insulin resistance, dyslipidemia, metabolic Syndrome X and central obesity, more preferably/Type 2 diabetes, impaired glucose tolerance and central obesity.
- a pharmaceutical composition as described above for the treatment of conditions associated with 11 ⁇ -HSD1 oxoreductase activity preferably, impaired glucose tolerance, Type 1 or Type 2 diabetes, insulin resistance, dyslipidemia, metabolic Syndrome X and central obesity.
- a unit dosage for a mammal of about 50 to 70 kg may contain between about 1 mg and 1000 mg, advantageously between about 5 to 500 mg of the active ingredient.
- the therapeutically effective dosage of active compound is dependent on the species of warmblooded animal (mammal), the body weight, age and individual condition, on the form of administration, and on the compound involved.
- the compounds of the present invention are inhibitors of 11 ⁇ -HSD1, and thus may be employed for the treatment of conditions associated with increased 11 ⁇ -HSD1 oxoreductase activity.
- Such compounds may therefore be employed for the treatment of conditions in which elevated local tissue concentrations of hormonally active glucocorticoids, such as cortisol in man, are implicated, e.g., Syndrome-X, dyslipidemia, hypertension, central obesity, and insulin resistance and hyperglycemia in Type 2 diabetes.
- hormonally active glucocorticoids such as cortisol in man
- the present invention relates to:
- a compound of the invention for use as a medicament.
- a pharmaceutical composition for use in conditions associated with 11 ⁇ -HSD1 oxoreductase activity comprising a compound of formula (I) in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefore.
- a method for the prevention and/or treatment of conditions associated with 11 ⁇ -HSD1 oxoreductase activity which comprises administering a therapeutically effective amount of a compound of the present invention.
- a therapeutic combination e.g. a kit, kit of parts e.g. for use in any method as defined herein, comprising a compound of formula (I), in free form or in pharmaceutically acceptable salt form, to be used concomitantly or in sequence with at least one pharmaceutical composition comprising at least another therapeutic agent, preferably selected from antidiabetics, hypolipidemic agents, anti-obesity agents, anti-hypertensive agents or inotropic agents.
- the kit may comprise instructions for its administration.
- a kit of parts comprising
- a pharmaceutical composition of the invention (ii ) a pharmaceutical composition comprising a compound selected from an antidiabetic, anti-obesity agent, anti-hypertensive agent, inotropic agent or hypolipidemic agent, or a pharmaceutically acceptable salt thereof, in the form of two separate units of the components (i) to (ii).
- a method as defined above comprising co-administration, e.g.
- a therapeutically effective amount of a compound of formula (I) in free form or in pharmaceutically acceptable salt form and a second drug substance, said second drug substance being a antidiabetic, anti-obesity agent, anti-hypertensive agent, inotropic agent or hypolipidemic agent, e.g. as indicated above.
- a compound of the invention is administered to a mammal in need thereof.
- a compound of the invention is used for the treatment of a disease which responds to inhibition of 11 ⁇ -HSD1 oxoreductase activity.
- the conditions associated with increased 11 ⁇ *-HSD1 oxoreductase activity are selected frdm impaired glucose tolerance, Type 1 or Type 2 diabetes, insulin resistance, dyslipidemia, metabolic Syndrome X and central obesity, most preferably Type 2 diabetes, impaired glucose tolerance and central obesity.
- a method or use according to the invention which comprises administering said compound in combination with a therapeutically effective amount of an antidiabetic agent, anti-obesity agent, anti-hypertensive agent, inotropic agent or hypolipidemic agent.
- a method or use according to the invention which comprises administering saidpornpound in the form of a pharmaceutical composition as described herein.
- treatment embraces all the different forms or modes of treatment as known to those of the pertinent art and in particular includes preventive, curative, delay of progression and palliative treatment.
- a therapeutically effective amount in vivo may range depending on the route of administraton, between about 1 and 500 mg/kg, preferably between about 5 and 100 mg/kg.
- the activity of a compound according to the present invention can be assessed by the following methods or methods well described in the art:
- Recombinant human 11 ⁇ -HSD1 is expressed in yeast Pichia pastoris. Cultures are grown at 30°C for 3 days in the presence of methanol to induce enzyme expression. The microsomal fraction overexpressing 11 ⁇ -HSD1 is prepared from the cell homogenate and used as the enzyme source for primary screening. A test compound at the desired concentration is pre- incubated for 10 min at RT with 3 ⁇ g of the microsomal protein in 50 mM sodium phosphate, pH 7.5, in a total volume of 80 ⁇ L.
- the enzyme reaction is initiated by adding 20 ⁇ L of a mixture containing 5 mM NADPH, 500 nM cortisone, and 80,000 dpm of [ 3 H]cortisone in the same buffer and is terminated by ethyl acetate after incubation for 90 min at 37°C.
- the production of [ 3 H]cortisol is quantitated upon separation from [ 3 H]cortisone by a C t8 column on HPLC equipped with a radioactivity detector.
- Glycerrhetinic acid a known inhibitor of 11 ⁇ -HSD1 is used as a standard.
- the SW-620 human colon carcinoma cell line is obtained from the American Type Culture Collection (ATCC). Cells are plated at a density of 8-10 x 10 4 cells/cm 2 in DMEM/F12 Containing 5% BCS, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin and 0.25 ⁇ g/L ⁇ amphotericin B. Cultures are grown to 80-90% confluence in a humidified atmosphere of 5% CO 2 at 37°C. The medium is changed to serum-free, phenol red-free DMEM/F12 at 24 h before harvesting the cells.
- ATCC American Type Culture Collection
- Dehydrogenase activity is quantified by measuring the conversion of [ 3 H]cortisol to [ 3 H]cortisone using lysates of SW-620 cells as the enzyme source.
- the assay is performed in tubes containing Kreb's-Ringer buffer pH 7.4, with 0.20 mM NAD and 200,000 dpm of [ 3 H]cortisol and a test compound in a total volume of 1 mL.
- the tubes are preincubated for 10 min at 37°C before adding 200 ⁇ g of cell lysates to start the reaction. After incubation for 1 h at 37°C in a shaking water bath, the mixture is extracted with 2 volumes of ethyl acetate and centrifuged for 10 min at 2,000 rpm.
- the organic layer is collected, dried under vacuum and resuspended in methanol.
- the dissolved residues are quantitatively transferred to thin layer plates and developed in chloroform-methanoi (90:10). Unlabeled cortisol and cortisone were used as reference markers.
- the TLC plates are scanned on a Bioscan radioimaging detector (Bioscan, Washington, DC), and the fractional conversion of cortisol to cortisone is calculated. Enzyme activity is expressed as pmoles of product formed per mg protein per hour. Carbenoxolone and glycyrrhetinic acid are used as standards.
- the inhibition of cellular 11 ⁇ -HSD1 activity in primary rat hepatocytes is determined as follows:
- mice Male Sprag ⁇ e-Dawley rats weighing 180-200 g are anesthetized with sodium pentobarbital (65 mg/kg).
- the liver is perfused in situ with calcium-free Earl's Balanced Salt Solution (EBSS) followed by EBSS containing 100-150 U/mL of collagenase, 1.8 mM CaCI 2 and 10 mM HEPES, pH 7.4.
- EBSS calcium-free Earl's Balanced Salt Solution
- the perfuse'd liver is removed and aseptically placed in warm William's Medium E containing 10% BCS. After decapsulation, the organ is transferred to fresh medium and gently shaken to facilitate tissue dissociation and cell release. Hepatocytes are separated from nonparenchymal and dead cells by repeated low speed centrifugation. Cell viability is determined by trypan blue exclusion.
- Hepatocytes are plated on collagen coated dishes at a density of 1 x 10 5 cells/cm 2 jrj c ⁇ ⁇ William's medium E containing 10% BCS, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 0.25 ⁇ g/mL amphotericin B, 2 mM L-glutamine, 10 mM HEPES, 100 nM insulin an,d 1 nM dexamethasone. After 1 h the medium is changed to serum-free William's medium E supplemented as described above. Thereafter, the medium is replaced every 24 h. The cultures are maintained in a humidified atmosphere of 5% CO 2 at 37°C.
- Enzyme activity is measured in the medium of primary cultures of rat hepatocytes 48 h after plating the cells.
- the medium is aspirated and replaced with serum-free William's medium E containing 2 nM [ 3 H]11-dehydrocorticosterone and a test compound and is incubated for 2 h.
- An aliquot of culture medium is removed at the end of the incubation and the mixture is extracted with 2 volumes of ethyl acetate, dried under vacuum and resuspended in methanol. The dissolved residues are quantitatively transferred to thin layer plates and developed in chloroform-methanoi (90:10).
- the TLC plates are scanned on a Bioscan imaging detector and the fractional conversion of 11-dehydrocorticosterone to corticosterone is calculated.
- the cell layer is rinsed with cold phosphate-buffered saline and dissolved in 0.1 N NaOH/5% SDS for the determination of cellular protein (BCA, Pierce, Rockford, IL). Enzyme activity is expressed as pmoles of product formed per mg protein per hour.
- ADX mice Inhibition of corticosterone production in adrenalectomized (ADX) mice is determined as follows:
- Bilateral adrenalectomy is performed in male mice of the CD1 strain (6 to 8 weeks of age, 25-30 g body weight) through a lumbar laparotomy. After 0 days the animals are fasted for 24 h. Compounds are administered orally at 25 mg/kg each at 2 and 4 h before sacrifice. A second group of animals receives carbenoxolone at the same dose, and a third group receives the vehicle (cornstarch). Homogenized liver samples are used to measure corticosterone concentration which is determined by radioimmunoassay and is expressed as pg of corticosterone per mg of liver protein.
- ⁇ /-cyclohexylmethyl-4-fluorobenzoylamfno- ⁇ /-methylbenzamide may be prepared as follows:
- solutions of NMM (2.0 M in THF, 126 ⁇ L, 0.225 mmol) and 4-fluorobenzoyl chloride (1.0 M in THF, 195 ⁇ L, 0.195 mmol) are dispensed sequentially into a vial containing a solution of the title C compound, 4-amino-/V- cyclohexylmethyl- -methylbenzamide in ⁇ /, ⁇ /-dimethylformamide (DMF, 0.30 M, 4500 ⁇ L, 0.15 mmol).
- the vial is shaken at RT for 5 h, then PS Trisamine (Argoscoop set at 0.5, Argonaut Technologies, Inc.) is added to the vial.
- Example 2 The following compounds are prepared analogously to Example 1 by treating the title C compound in Example 1 with the appropriate activated derivative bf a carboxylic acid.
- the sodium salt of the title A compound, ⁇ 4-[(cyclohexylmethyl)methylcarbamoyl]- phenyl ⁇ carbamic acid allyl ester is prepared in a 3 mL volumetric flask by dissolving the title A compound (330 mg, 1.00 mmol) in 2 mL of THF, adding NaH (60% suspension in mineral oil, 44 mg, 1.1 mmol), and diluting the mixture to 3 mL of total volume with DMF. The mixture is shaken for 10 min and used immediately.
- Example 5 The following compounds are prepared analogously to Example 5 by converting jhe tje A compound in Example 5 to its sodium salt, treating the sodium salt with the appropriate alkylating agent followed by deallylation.
- the catalyst is removed by vacuum filtration through Celite, and the filtrate is concentrated to give (4-aminophenyl)-(4aS*,8aR * )-octahydro-1(2H)-quinolin-1 -yl-methanone.
- the product is used as such in the following step.
- Example 9 The following compounds are prepared analogously to Examples 9 and 10 using either the title B compound in Example 9 or the title A compound in Example 10 and the appropriate N- derivatizing agent, such as an activated derivative of a carboxylic acid, a chloroformate, a sulfonyl chloride, an isocyanate or a thioisocyanate.
- N- derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate, a sulfonyl chloride, an isocyanate or a thioisocyanate.
- Example 9 The following compounds are prepared analogously to Example 9 starting from 2-ctyoro-4- nitrobenzoyl chloride and decahydroquinoline and treating the intermediate 4-amino-2- chlorobenzamide derivative analogous to the title B compound in Example 9 with the appropriate ⁇ /-derivatizing agent, such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- the appropriate ⁇ /-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- Example 9 The following compounds are prepared analogously to Example 9 starting from 2-methoxy- 4-nitrobenzoyl chloride or 3-methoxy-4-nitrobenzoyl chloride and decahydro-quinoline, and treating the intermediate 4-amino-2-methoxybenzamide or 4-amino-3-methoxybenzamide derivatives analogous to the title B compound in Example 9 or the title A compound in Example 10 with the appropriate /V-derivatizing agent, such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- the appropriate /V-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- Oxalyl chloride (0.65 mL, 7.47 mmol) is added dropwise to a solution of the title C compound, 2-allyloxy-4-nitrobenzoic acid (1.11 g, 4.98 mmol) in 0.50 mL DMF and 40 mL CH 2 CI 2 at 0°C.
- the reaction is stirred at 0°C for 1 h then NMM (1.37 mL, 12.45 mmol) and decahydroquinoline (832 mg, 5.97 mmol) are added sequentially.
- the reaction is warmed to
- a solution of NMM (2.0 ' inTHF, 135 ⁇ L, 0.27 mol) and a solution of 2,4-dichlorobenzoyl chloride (1.0 M in THF, 225 ⁇ L, 0.225 mmol) are dispensed sequentially into a vial containing a solution of tlie title E » compound, (4-amino-2-propoxyphenyl)-[octahydro-1(2H)-quinolin-1-yl]-methanone (0.60 M in DMF, 250 ⁇ L, 0.15 mmol).
- the vial is shaken at RT for 16 h.
- a solution of aqueous lithium hydroxide (1.5 N, 100 ⁇ L, 0.15 mmol) is dispensed into the vial, and the vial is shaken for 20 min.
- the reaction mixture is acidified with 50 ⁇ L TFA and purified by HPLC to afford 2,4- dichloro-/V-[4-(octahydro-1(2H)-quinoline-1-carbonyl)-3-propoxyphenyl]benzamide: API-MS 489 [M+H]*.
- Example 18 the following compounds are prepared analogously to Example 17 by treating the title E compound in Example 17 with the appropriate ⁇ /-derivatizing agent, such as an activated derivative of a carboxylic acid or a chloroformate.
- the appropriate ⁇ /-derivatizing agent such as an activated derivative of a carboxylic acid or a chloroformate.
- the concentrate is partitioned between 5 mL of water and 5 mL of dichloromethane.
- the aqueous layer is separated and made acidic by the addition of 1 N aqueous HCl.
- the precipitate is collected by filtration, washed with water and dried to give 4-[(3,4-dimethoxy- benzoyl)-amino]-1 -naphthalene carboxylic acid: m.p.
- 1,4-Naphthalene dicarboxylic acid (12 g, 55.5 mmol) is suspended in 200 mL of MeOH. Hydrogen chloride gas is bubbled through for 10 min and the reaction is refluxed overnight. The resulting mixture is cooled to RT, then concnetrated under reduced pressure. Flash chromatograhpy on silica (eluant: 33% EtOAc in hexane) gives methyl 1 ,4-napthalene dicarboxylate as a whilte soild: NMR (CDCI 3 ) 4.01 (6H, s), 7.63 (2H, dd), 8.09 (2H, s), 8.82 (2H, dd).
- the orgahic layer is ; , collected, dried over anhydrous Na 2 SO 4 , and concentrated in vacuo to give methyl 1,4-naphthalene monocarboxylate as a white solid: NMR (DMSO-c 6 ) 3.98 (3H, s), 7.71 (2H, dd), 8.1 (2H, s), 8.7 (1H, dd), 8.78-8.86 (1 H, m).
- reaction mixture is allowed to stirred at RT for 4 h.
- the reaction mixture is poured into water and extracted with EtOAc.
- the combined organic extracts are washed successively with 1 N aqueous HCl, water, saturated aqueous NaHCO 3 , water, and the organic solution is dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure.
- a solution of aqueous lithium hydroxide (1.5 N, 100 ⁇ L, 0.15 mmol) is dispensed into the vial, and the vial is agitated for 20 min.
- the reaction mixture is diluted with 500 ⁇ L DMF, acidified with 50 ⁇ L TFA and purified by HPLC to afford of (4-fluoro-phenyl)- ⁇ 5-[(4aS*,8aR*)-octahydro-1 (2H)-quinoline-1-carbonyl]-2,3- dihydro-indol-1-yl ⁇ -methanone: API-MS 408 [M+H]*.
- Example 32 The following compounds are prepared analogously to Example 32 by treating the title E compound in Example 32 with the appropriate /V-derivatizing agent such as an activated derivative of a carboxylic acid, a sulfonyl chloride, a chloroformate or an isocyanate.
- the appropriate /V-derivatizing agent such as an activated derivative of a carboxylic acid, a sulfonyl chloride, a chloroformate or an isocyanate.
- Benzoyl chloride (104 mg, 0.74 mmol) is added to a solution of the title B compound, [5-(3- aminophenyl)-furan-2-yl]-(4aS*,8aR * )-octahydro-1 (2H)-quinolin-1 -yl-methanone (200 mg, 0.61 mmol) and triethylamine (125 mg, 1.23 mmol) in dichloromethane (5 mL) at RT.
- Example 9 The following compounds are prepared analogously to Example 9 starting from 3-nitrobenzoyl chloride and decahydroquinoline, and treating the intermediate 3-amino- benzamide derivative analogous to the title B compound in Example 9 with the appropriate /V-derivatizing agent, such as an activated derivative of a carboxylic acid, a chloroformate, an isocyanate or a thioisocyanate.
- the appropriate /V-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate, an isocyanate or a thioisocyanate.
- (4aS*,8aS*)-Octahydro-quinoline-2,6-dione ethylene glycol ketal may be prepared according to methods described by Kozikowski et al., J. Org. Chem., Vol. 56, p. 4636 (1991) and Langlois et al., Bull. Soc. Chim. Fr., Vol. 130, p. 655 (1993).
- Example 9 The following compounds are prepared analogously to Example 9 starting from 4-nitrobenzoyl chloride and either trans or cis decahydroisoquinoline, and treating the intermediate 4-aminobenzamide * derivative with the appropriate ⁇ /-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- the appropriate ⁇ /-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- Example 9 The following compounds are prepared analogously to Example 9 starting from 2-chloro-4- nitrobenzoyl chloride and either trans or cis decahydroisoquinoline, and treating the intermediate 4-amino-2-chlorobenzamide derivative with the appropriate ⁇ /-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- the appropriate ⁇ /-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- Example 9 The following compounds are prepared analogously to Example 9 starting from 2-methoxy- 4-nitrobenzoyl chloride and either trans or cis decahydroisoquinoline, and treating the intermediate 4-amino-2-methoxybenzamide derivative with the appropriate /V-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- the appropriate /V-derivatizing agent such as an activated derivative of a carboxylic acid, a chloroformate or an isocyanate.
- reaction mixture is degassed, and then heated at 100°C for 2 h.
- Toluene is removed by rotary evaporation, and the residue is dissolved in 10 mL of THF.
- the solution is treated with with 1 N aqueous HCl (5 mL, 5.00 mmol) and stirred at RT for 2 h.
- the reaction is made basic with 1 N aqueous NaOH, and partitioned between EtOAc and water. The organic layer is washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated.
- reaction mixture is degassed, and then heated at 90°C for 3 h.
- Toluene is removed by rotary evaporation, and the residue is dissolved in 15 mL of THF/water - 4/1.
- the solution is treated ith with 1 N aqueous HCl (10 mL, 10 mmol) and stirred at RT for 1 h.
- the reaction is quenched with 1 N aqueous NaOH, and partitioned between EtOAc and water. The organic layer is washed with brine, dried over anhydrous Na SO 4 , and concentrated.
- reaction mixture is acidified with 50 ⁇ L of TFA and purified by HPLC to afford ⁇ /-(2-benzyl-1-o ⁇ o-1 ,2,3,4-tetrahydro-isoquinolin-6-yl)-2,4-dichloro- benzamide- API-MS 425 [M+1] *.
- THF 222 ⁇ L, 0.220 mmol
- the vial is shaken at RT for 16 h and the solids are removed by filtration.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002513349A CA2513349A1 (en) | 2003-01-24 | 2004-01-23 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 |
US10/542,759 US20060205772A1 (en) | 2003-01-24 | 2004-01-23 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I |
BR0406938-2A BRPI0406938A (pt) | 2003-01-24 | 2004-01-23 | Derivados de amida e seu uso como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 |
EP04704554A EP1590319A1 (en) | 2003-01-24 | 2004-01-23 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 |
JP2006500009A JP2006517199A (ja) | 2003-01-24 | 2004-01-23 | アミド誘導体およびそれらの11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ・タイプ1の阻害剤としての使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44253203P | 2003-01-24 | 2003-01-24 | |
US60/442,532 | 2003-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004065351A1 true WO2004065351A1 (en) | 2004-08-05 |
Family
ID=32772048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/000571 WO2004065351A1 (en) | 2003-01-24 | 2004-01-23 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 |
Country Status (10)
Cited By (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006024628A1 (en) * | 2004-08-30 | 2006-03-09 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
JP2006522748A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物 |
WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
WO2006132197A1 (ja) | 2005-06-07 | 2006-12-14 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
WO2006135667A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidiazo -and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006135795A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006138508A2 (en) | 2005-06-17 | 2006-12-28 | Amgen Inc. | Benzamide derivatives and uses related thereto |
WO2007003521A2 (en) * | 2005-07-05 | 2007-01-11 | F. Hoffmann-La Roche Ag | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors |
WO2005070893A3 (en) * | 2004-01-09 | 2007-01-18 | Corcept Therapeutics Inc | Azadecalin glucocorticoid receptor modulators |
WO2007017728A2 (en) * | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Novel heterocyclic compounds |
WO2007025892A1 (en) | 2005-08-31 | 2007-03-08 | F. Hoffmann-La Roche Ag | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
WO2007038138A2 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2007051810A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
US7217838B2 (en) | 2005-01-05 | 2007-05-15 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2007067504A2 (en) | 2005-12-05 | 2007-06-14 | Incyte Corporation | Lactam compounds and methods of using the same |
WO2007068330A1 (en) | 2005-12-16 | 2007-06-21 | Merck Patent Gmbh | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS |
WO2007114124A1 (ja) | 2006-03-30 | 2007-10-11 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するイソキサゾール誘導体およびイソチアゾール誘導体 |
WO2007130898A1 (en) | 2006-05-01 | 2007-11-15 | Incyte Corporation | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 |
WO2007128761A2 (de) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Verwendungen von dpp iv inhibitoren |
US7304081B2 (en) | 2004-05-07 | 2007-12-04 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2007145835A2 (en) * | 2006-06-08 | 2007-12-21 | Amgen Inc. | Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity |
WO2008003611A1 (en) * | 2006-07-05 | 2008-01-10 | F. Hoffmann-La Roche Ag | Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1) |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
US7345058B2 (en) | 2005-04-05 | 2008-03-18 | Hoffmann-La Roche Inc. | Pyrazoles |
WO2007145834A3 (en) * | 2006-06-08 | 2008-04-03 | Amgen Inc | Benzamide derivatives and uses related thereto |
WO2008053194A2 (en) * | 2006-11-03 | 2008-05-08 | Astrazeneca Ab | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
JP2008515826A (ja) * | 2004-10-04 | 2008-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
DE102006058207A1 (de) * | 2006-12-11 | 2008-06-19 | Universitätsklinikum Schleswig-Holstein | Verfahren zur Herstellung spezifischer Inhibitoren der 11beta-Hydroxysteroid-Dehydrogenase Typ 1 mit Nor-Oleanan- oder Nor-Ursan-Grundgerüsten |
WO2008074384A1 (en) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS |
DE102007005045A1 (de) | 2007-01-26 | 2008-08-07 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2008157752A1 (en) | 2007-06-21 | 2008-12-24 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
EP2036548A1 (en) | 2003-09-22 | 2009-03-18 | onepharm Research & Development GmbH | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
US7511175B2 (en) | 2005-01-05 | 2009-03-31 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
JP2009526800A (ja) * | 2006-02-13 | 2009-07-23 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病の処置用のヘテロ二環式スルホンアミド誘導体 |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
US7618980B2 (en) | 2004-07-14 | 2009-11-17 | Bristol-Myers Squibb Company | Pyrrolo(oxo)quinolines as 5HT ligands |
US7632838B2 (en) | 2006-02-07 | 2009-12-15 | Wyeth | 11-beta HSD1 inhibitors |
US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US7714136B2 (en) | 2005-05-25 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes |
US7714135B2 (en) | 2005-02-09 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
US7714134B2 (en) | 2004-06-11 | 2010-05-11 | 4Sc Ag | Compounds and use of tetrahydropyridothiophenes |
US7723523B2 (en) | 2004-05-28 | 2010-05-25 | 4Sc Ag | Tetrahydropyridothiophenes |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US7741488B2 (en) | 2005-02-11 | 2010-06-22 | 4Sc Ag | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer |
WO2010083264A1 (en) * | 2009-01-15 | 2010-07-22 | Abbott Laboratories | Novel benzenesulfonamides as calcium channel blockers |
US7763728B2 (en) | 2005-05-25 | 2010-07-27 | 4Sc Ag | Tetrahydropyridothiophenes |
US7816391B2 (en) | 2007-02-12 | 2010-10-19 | Astrazeneca Ab | Chemical compounds |
US7838544B2 (en) | 2006-05-17 | 2010-11-23 | Incyte Corporation | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same |
WO2010139967A1 (en) | 2009-06-04 | 2010-12-09 | Xention Limited | Dihydroindole and tetrahydroisoquinoline derivatives useful as potassium channel inhibitors |
WO2010139953A1 (en) | 2009-06-04 | 2010-12-09 | Xention Limited | Compounds |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8012955B2 (en) | 2006-12-28 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8076376B2 (en) | 2005-07-22 | 2011-12-13 | Powers Jay P | Aniline sulfonamide derivatives and their uses |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
US8093265B2 (en) | 2007-03-09 | 2012-01-10 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8258138B2 (en) | 2008-08-29 | 2012-09-04 | Xention Limited | Potassium channel blockers |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012134233A2 (ko) | 2011-03-31 | 2012-10-04 | 한국화학연구원 | 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 |
US8288417B2 (en) | 2004-06-24 | 2012-10-16 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US8344181B2 (en) | 2004-08-30 | 2013-01-01 | Janssen Pharmaceutica N.V. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US8372841B2 (en) | 2004-04-29 | 2013-02-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8372840B2 (en) | 2008-08-29 | 2013-02-12 | Xention Limited | Potassium channel blockers |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8524894B2 (en) | 2009-06-04 | 2013-09-03 | Laboratorios Salvat, S.A. | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US8673901B2 (en) | 2008-08-29 | 2014-03-18 | Xention Limited | Potassium channel blockers |
US8716345B2 (en) | 2005-01-05 | 2014-05-06 | Abbvie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
US8927549B2 (en) | 2008-11-21 | 2015-01-06 | High Point Pharmaceuticals, Llc | Adamantyl benzamide derivatives |
US8940902B2 (en) | 2006-04-07 | 2015-01-27 | Abbvie Inc. | Treatment of central nervous system disorders |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9012494B2 (en) | 2004-05-07 | 2015-04-21 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9150512B2 (en) | 2004-08-30 | 2015-10-06 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2016095205A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2017070026A1 (en) | 2015-10-19 | 2017-04-27 | Schlumberger Technology Corporation | Corrosion inhibition |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10047082B2 (en) | 2013-11-25 | 2018-08-14 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
AU2018203354B2 (en) * | 2011-12-21 | 2019-12-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10759749B2 (en) | 2016-08-31 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic agent for diabetes |
US10787745B2 (en) | 2014-12-05 | 2020-09-29 | Schlumberger Technology Corporation | Corrosion inhibition |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US11058670B2 (en) | 2019-02-22 | 2021-07-13 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
WO2021159015A1 (en) * | 2020-02-07 | 2021-08-12 | Cytokinetics, Inc. | Nampt modulators |
WO2021236449A1 (en) * | 2020-05-18 | 2021-11-25 | Gen1E Lifesciences Inc. | P38alpha mitogen-activated protein kinase inhibitors |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11357781B2 (en) | 2016-06-23 | 2022-06-14 | University Of Maryland, Baltimore | Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11390581B2 (en) | 2020-10-29 | 2022-07-19 | Gen1E Lifesciences Inc. | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
US11555020B2 (en) | 2021-03-23 | 2023-01-17 | Gen1E Lifesciences Inc. | Substituted naphthyl p38α mitogen-activated protein kinase inhibitors |
US11718595B2 (en) | 2018-12-07 | 2023-08-08 | University Of Maryland, Baltimore | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors |
US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2531279A1 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
GB0521716D0 (en) * | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
ZA200904916B (en) * | 2007-02-23 | 2010-09-29 | High Point Pharmaceuticals Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
JP2009035513A (ja) * | 2007-08-02 | 2009-02-19 | Ube Ind Ltd | 4−n−(メチルベンゾイル)アミノ−2−メチル安息香酸の製法 |
US8304539B2 (en) * | 2008-02-07 | 2012-11-06 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
CN102099357B (zh) | 2008-04-23 | 2014-07-02 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
NZ594556A (en) * | 2009-01-28 | 2013-11-29 | Rigel Pharmaceuticals Inc | Carboxamide compounds and methods for using the same |
US9035059B2 (en) * | 2011-03-14 | 2015-05-19 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing condensed heterocyclic compound |
TW201609665A (zh) * | 2013-11-05 | 2016-03-16 | 赫孚孟拉羅股份公司 | 作為RORc調節劑的嗒衍生物 |
US9255096B1 (en) | 2014-10-07 | 2016-02-09 | Allergan, Inc. | Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH242949A (de) * | 1942-12-11 | 1946-06-15 | Ag J R Geigy | Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid. |
DE817911C (de) * | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
US3646048A (en) * | 1970-02-02 | 1972-02-29 | American Cyanamid Co | N-(tert-aminoalkyl)-2-indenecarboxamides |
DE2316644A1 (de) * | 1972-04-03 | 1973-10-18 | Robins Co Inc A H | Mittel mit antiemetischer aktivitaet |
DE2242007A1 (de) * | 1972-08-26 | 1974-03-14 | Basf Ag | Verfahren zur herstellung von phthalimidinen |
DE2459380A1 (de) * | 1973-12-17 | 1975-06-19 | Lilly Industries Ltd | Verfahren zur herstellung von oxazolderivaten |
DE2505447A1 (de) * | 1974-02-19 | 1975-08-21 | Sandoz Ag | Verfahren zur herstellung neuer carbocyclischer verbindungen |
US3963745A (en) * | 1972-04-03 | 1976-06-15 | A. H. Robins Company, Incorporated | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides |
DE2625285A1 (de) * | 1975-06-05 | 1976-12-23 | Lilly Industries Ltd | Heteroarylverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel |
DE2756771A1 (de) * | 1976-12-23 | 1978-06-29 | Ciba Geigy Ag | Verfahren zur herstellung von neuen substituierten 5-amino-2-pyridincarbonsaeure-verbindungen |
WO1994001113A1 (en) * | 1992-07-02 | 1994-01-20 | Otsuka Pharmaceutical Company, Limited | Oxytocin antagonist |
WO2001090094A1 (en) * | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2003040108A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9408185D0 (en) * | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
UA74145C2 (uk) * | 1999-04-30 | 2005-11-15 | Пфайзер Продактс Інк. | Модулятори глюкокортикоїдного рецептора |
EP1437344A4 (en) * | 2001-09-28 | 2006-09-20 | Takeda Pharmaceutical | BENZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
US7074788B2 (en) * | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
CA2478050A1 (en) * | 2002-03-01 | 2003-09-12 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
-
2004
- 2004-01-20 TW TW093101445A patent/TW200503994A/zh unknown
- 2004-01-21 PE PE2004000085A patent/PE20041040A1/es not_active Application Discontinuation
- 2004-01-22 AR ARP040100172A patent/AR043355A1/es unknown
- 2004-01-23 JP JP2006500009A patent/JP2006517199A/ja active Pending
- 2004-01-23 CA CA002513349A patent/CA2513349A1/en not_active Abandoned
- 2004-01-23 CN CN200480002540A patent/CN100586927C/zh not_active Expired - Fee Related
- 2004-01-23 BR BR0406938-2A patent/BRPI0406938A/pt not_active IP Right Cessation
- 2004-01-23 EP EP04704554A patent/EP1590319A1/en not_active Withdrawn
- 2004-01-23 WO PCT/EP2004/000571 patent/WO2004065351A1/en active Application Filing
- 2004-01-23 US US10/542,759 patent/US20060205772A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH242949A (de) * | 1942-12-11 | 1946-06-15 | Ag J R Geigy | Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid. |
DE817911C (de) * | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
US3646048A (en) * | 1970-02-02 | 1972-02-29 | American Cyanamid Co | N-(tert-aminoalkyl)-2-indenecarboxamides |
US3963745A (en) * | 1972-04-03 | 1976-06-15 | A. H. Robins Company, Incorporated | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides |
DE2316644A1 (de) * | 1972-04-03 | 1973-10-18 | Robins Co Inc A H | Mittel mit antiemetischer aktivitaet |
DE2242007A1 (de) * | 1972-08-26 | 1974-03-14 | Basf Ag | Verfahren zur herstellung von phthalimidinen |
DE2459380A1 (de) * | 1973-12-17 | 1975-06-19 | Lilly Industries Ltd | Verfahren zur herstellung von oxazolderivaten |
DE2505447A1 (de) * | 1974-02-19 | 1975-08-21 | Sandoz Ag | Verfahren zur herstellung neuer carbocyclischer verbindungen |
DE2625285A1 (de) * | 1975-06-05 | 1976-12-23 | Lilly Industries Ltd | Heteroarylverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel |
DE2756771A1 (de) * | 1976-12-23 | 1978-06-29 | Ciba Geigy Ag | Verfahren zur herstellung von neuen substituierten 5-amino-2-pyridincarbonsaeure-verbindungen |
WO1994001113A1 (en) * | 1992-07-02 | 1994-01-20 | Otsuka Pharmaceutical Company, Limited | Oxytocin antagonist |
WO2001090094A1 (en) * | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2003040108A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
Non-Patent Citations (44)
Title |
---|
D'AMBROSIO,M ET AL., HELV.CHIM.ACTA 77, 1994, pages 1895 - 1902 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283307, Database accession no. BRN 1495585 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283308, Database accession no. BRN 191521 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283309, Database accession no. BRN 8063205 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283310, Database accession no. BRN 7830645 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283311, Database accession no. BRN 1478254 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283312, Database accession no. BRN 162332 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283313, Database accession no. BRN 159707 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283314, Database accession no. BRN 51769 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283315, Database accession no. BRN 33652 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283316, Database accession no. BRN 165343 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283317, Database accession no. BRN 163468 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283318, Database accession no. BRN 188711 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283319, Database accession no. BRN 2795420 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283320, Database accession no. BRN 2767378, 334696 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283321, Database accession no. BRN 2866741 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283322, Database accession no. BRN 2911920 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283323, Database accession no. BRN 3107560 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283324, Database accession no. BRN 3102366 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283325, Database accession no. BRN 3008054 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283326, Database accession no. BRN 2816857 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283327, Database accession no. BRN 4194118 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002283328, Database accession no. BRN 6808236 * |
FISHER,M.J. ET AL., TETRAHEDRON LETT., vol. 38, no. 33, 1997, pages 5747 - 5750 * |
GANELLIN,C.R. ET AL., J.MED.CHEM., vol. 39, no. 19, 1996, pages 3806 - 3813 * |
GIRARD ET AL., C.R.HEBD.SEANCES ACAD.SCI. 251, 1960, pages 164 * |
GORVIN, J.CHEM.SOC., 1945, pages 732 - 735 * |
GRAMMATICAKIS, BULL.SOC.CHIM.FR., 1968, pages 1057 * |
GUTHRIE,R. W. ET AL., J.MED.CHEM., vol. 33, no. 10, 1990, pages 2856 - 2864 * |
IWAKURA,Y. ET AL., J.ORG.CHEM. 31, 1966, pages 142 - 146 * |
JOHNSTON, T.P. ET AL., J.MED.CHEM. 9, 1966, pages 892 - 911 * |
MACKIE;CUTLER, J.CHEM.SOC., 1954, pages 2577 * |
MCMILLAN ET AL., J.AMER.CHEM.SOC. 78, 1956, pages 4077 - 4080 * |
MURAHASHI ET AL., BULL.CHEM.SOC.JPN. 33, 1960, pages 81 - 87 * |
NANNINI,G ET AL., ARZNEIM.FORSCH. 23, 1973, pages 1090 - 1100 * |
PAPA ET AL., J.AMER.CHEM.SOC. 72, 1950, pages 3885 * |
PECHERER ET AL., HELV.CHIM.ACTA 54, 1971, pages 743 - 747 * |
POLLARD;ADELSON, J.AMER.CHEM.SOC. 56, 1934, pages 150 * |
SCHINDLBAUER,H., MONATSH.CHEM. 99, 1968, pages 1799 - 1807 * |
SUSTER ET AL., J.MED.CHEM. 21, 1978, pages 1165 * |
SWAMINATHAN;SULOCHANA, J.ORG.CHEM. 23, 1958, pages 90 * |
WALLER,C.L. ET AL., J.PHARM.SCI., vol. 83, no. 4, 1994, pages 571 - 576 * |
WANG, X. ET AL., TETRAHEDRON LETT., vol. 39, no. 37, 1998, pages 6609 - 6612 * |
WINKELMANN,E.ET AL., ARZNEIM. FORSCH. 19, 1969, pages 543 - 558 * |
Cited By (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006522748A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物 |
EP2036548A1 (en) | 2003-09-22 | 2009-03-18 | onepharm Research & Development GmbH | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
US8324203B2 (en) | 2004-01-09 | 2012-12-04 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
US7678813B2 (en) | 2004-01-09 | 2010-03-16 | Corcept Therapeutics, Inc. | Azadecalin Glucocorticoid receptor modulators |
WO2005070893A3 (en) * | 2004-01-09 | 2007-01-18 | Corcept Therapeutics Inc | Azadecalin glucocorticoid receptor modulators |
US9133145B2 (en) | 2004-04-29 | 2015-09-15 | Abbvie Inc. | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8372841B2 (en) | 2004-04-29 | 2013-02-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US9776965B2 (en) | 2004-05-07 | 2017-10-03 | Janssen Pharmaceutica Nv | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9302987B2 (en) | 2004-05-07 | 2016-04-05 | Janssen Pharmaceutica N.V. | Pyrrolidinyl derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US8058288B2 (en) | 2004-05-07 | 2011-11-15 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
EP2963021A1 (en) | 2004-05-07 | 2016-01-06 | Incyte Holdings Corporation | Amido compounds and their use as pharmaceuticals |
US9126927B2 (en) | 2004-05-07 | 2015-09-08 | Incyte Holdings Corporation | Amido compounds and their use as pharmaceuticals |
US9012494B2 (en) | 2004-05-07 | 2015-04-21 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9957229B2 (en) | 2004-05-07 | 2018-05-01 | Incyte Holdings Corporation | Amido compounds and their use as pharmaceuticals |
US7304081B2 (en) | 2004-05-07 | 2007-12-04 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
US9670154B2 (en) | 2004-05-07 | 2017-06-06 | Incyte Holdings Corporation | Amido compounds and their use as pharmaceuticals |
US7776874B2 (en) | 2004-05-07 | 2010-08-17 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
US7723523B2 (en) | 2004-05-28 | 2010-05-25 | 4Sc Ag | Tetrahydropyridothiophenes |
US7803945B2 (en) | 2004-05-28 | 2010-09-28 | 4Sc Ag | Tetrahydropyridothiophenes |
US7714134B2 (en) | 2004-06-11 | 2010-05-11 | 4Sc Ag | Compounds and use of tetrahydropyridothiophenes |
US8288417B2 (en) | 2004-06-24 | 2012-10-16 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
US7618980B2 (en) | 2004-07-14 | 2009-11-17 | Bristol-Myers Squibb Company | Pyrrolo(oxo)quinolines as 5HT ligands |
US9630921B2 (en) | 2004-08-30 | 2017-04-25 | Janssen Pharmaceutica Nv | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
WO2006024628A1 (en) * | 2004-08-30 | 2006-03-09 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9422284B2 (en) | 2004-08-30 | 2016-08-23 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
CN101039908B (zh) * | 2004-08-30 | 2010-06-23 | 詹森药业有限公司 | 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物 |
US8563591B2 (en) | 2004-08-30 | 2013-10-22 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US8344181B2 (en) | 2004-08-30 | 2013-01-01 | Janssen Pharmaceutica N.V. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9150512B2 (en) | 2004-08-30 | 2015-10-06 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
JP2011157373A (ja) * | 2004-10-04 | 2011-08-18 | F Hoffmann La Roche Ag | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
JP2008515826A (ja) * | 2004-10-04 | 2008-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
US8563570B2 (en) | 2004-11-10 | 2013-10-22 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US8716345B2 (en) | 2005-01-05 | 2014-05-06 | Abbvie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7511175B2 (en) | 2005-01-05 | 2009-03-31 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
USRE41135E1 (en) | 2005-01-05 | 2010-02-16 | Abbott Laboratories | Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US9290444B2 (en) | 2005-01-05 | 2016-03-22 | Abbvie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8993632B2 (en) | 2005-01-05 | 2015-03-31 | Abbvie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8314270B2 (en) | 2005-01-05 | 2012-11-20 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7217838B2 (en) | 2005-01-05 | 2007-05-15 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7528282B2 (en) | 2005-01-05 | 2009-05-05 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7855308B2 (en) | 2005-01-05 | 2010-12-21 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US7714135B2 (en) | 2005-02-09 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
US7741488B2 (en) | 2005-02-11 | 2010-06-22 | 4Sc Ag | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer |
US7759339B2 (en) | 2005-03-31 | 2010-07-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
WO2006105127A3 (en) * | 2005-03-31 | 2007-03-22 | Takeda San Diego Inc | Hydroxysteroid dehydrogenase inhibitors |
JP2008534600A (ja) * | 2005-03-31 | 2008-08-28 | タケダ サン ディエゴ インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
US7345058B2 (en) | 2005-04-05 | 2008-03-18 | Hoffmann-La Roche Inc. | Pyrazoles |
EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7763728B2 (en) | 2005-05-25 | 2010-07-27 | 4Sc Ag | Tetrahydropyridothiophenes |
US7714136B2 (en) | 2005-05-25 | 2010-05-11 | 4Sc Ag | Tetrahydropyridothiophenes |
WO2006132197A1 (ja) | 2005-06-07 | 2006-12-14 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
US8952176B2 (en) | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
US8148396B2 (en) | 2005-06-09 | 2012-04-03 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EA013017B1 (ru) * | 2005-06-09 | 2010-02-26 | Бристол-Маерс Сквибб Компани | ТРИАЗОЛОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА I |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2006135795A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006135667A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidiazo -and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
CN102558176A (zh) * | 2005-06-09 | 2012-07-11 | 布里斯托尔-迈尔斯.斯奎布公司 | 作为I型11-β-羟基类固醇脱氢酶抑制剂的咪唑并吡啶和三唑并吡啶 |
US8158648B2 (en) | 2005-06-09 | 2012-04-17 | Li James J | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors |
AU2006259349B2 (en) * | 2005-06-17 | 2011-10-27 | Amgen Inc. | Benzamide derivatives and uses related thereto |
WO2006138508A2 (en) | 2005-06-17 | 2006-12-28 | Amgen Inc. | Benzamide derivatives and uses related thereto |
WO2006138508A3 (en) * | 2005-06-17 | 2007-02-01 | Amgen Inc | Benzamide derivatives and uses related thereto |
US8637576B2 (en) | 2005-06-17 | 2014-01-28 | Amgen Inc. | Benzamide derivatives and uses related thereto |
US7605289B2 (en) | 2005-06-17 | 2009-10-20 | Amgen, Inc. | Benzamide derivatives and uses related thereto |
WO2007003521A3 (en) * | 2005-07-05 | 2009-02-05 | Hoffmann La Roche | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors |
WO2007003521A2 (en) * | 2005-07-05 | 2007-01-11 | F. Hoffmann-La Roche Ag | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors |
US7678795B2 (en) | 2005-07-05 | 2010-03-16 | Hoffman-La Roche Inc. | Pyridazines as 11b-HSD1 inhibitors |
KR100979582B1 (ko) | 2005-07-05 | 2010-09-01 | 에프. 호프만-라 로슈 아게 | 피리다진 유도체 |
US8076376B2 (en) | 2005-07-22 | 2011-12-13 | Powers Jay P | Aniline sulfonamide derivatives and their uses |
WO2007017728A3 (en) * | 2005-08-05 | 2008-04-03 | Orchid Res Lab Ltd | Novel heterocyclic compounds |
WO2007017728A2 (en) * | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Novel heterocyclic compounds |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
WO2007025892A1 (en) | 2005-08-31 | 2007-03-08 | F. Hoffmann-La Roche Ag | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
WO2007038138A2 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2007038138A3 (en) * | 2005-09-21 | 2007-07-05 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
WO2007051810A3 (en) * | 2005-11-01 | 2008-01-24 | Novo Nordisk As | Pharmaceutical use of substituted amides |
WO2007051810A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
US8193207B2 (en) | 2005-12-05 | 2012-06-05 | Incyte Corporation | Lactam compounds and methods of using the same |
WO2007067504A2 (en) | 2005-12-05 | 2007-06-14 | Incyte Corporation | Lactam compounds and methods of using the same |
WO2007068330A1 (en) | 2005-12-16 | 2007-06-21 | Merck Patent Gmbh | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
US7632838B2 (en) | 2006-02-07 | 2009-12-15 | Wyeth | 11-beta HSD1 inhibitors |
JP2009526800A (ja) * | 2006-02-13 | 2009-07-23 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病の処置用のヘテロ二環式スルホンアミド誘導体 |
WO2007114124A1 (ja) | 2006-03-30 | 2007-10-11 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するイソキサゾール誘導体およびイソチアゾール誘導体 |
US8017638B2 (en) | 2006-03-30 | 2011-09-13 | Shionogi & Co., Ltd. | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 |
US8940902B2 (en) | 2006-04-07 | 2015-01-27 | Abbvie Inc. | Treatment of central nervous system disorders |
US9464072B2 (en) | 2006-04-07 | 2016-10-11 | Abbvie Inc. | Treatment of central nervous system disorders |
WO2007130898A1 (en) | 2006-05-01 | 2007-11-15 | Incyte Corporation | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 |
EP2351568A2 (de) | 2006-05-04 | 2011-08-03 | Boehringer Ingelheim International GmbH | Verwendungen von dpp iv Inhibitoren |
WO2007128761A2 (de) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Verwendungen von dpp iv inhibitoren |
US7838544B2 (en) | 2006-05-17 | 2010-11-23 | Incyte Corporation | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same |
WO2007145835A2 (en) * | 2006-06-08 | 2007-12-21 | Amgen Inc. | Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity |
WO2007145835A3 (en) * | 2006-06-08 | 2008-03-06 | Amgen Inc | Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity |
US7659287B2 (en) | 2006-06-08 | 2010-02-09 | Amgen Inc. | Benzamide derivatives and uses related thereto |
WO2007145834A3 (en) * | 2006-06-08 | 2008-04-03 | Amgen Inc | Benzamide derivatives and uses related thereto |
AU2007259144B2 (en) * | 2006-06-08 | 2012-04-19 | Amgen Inc. | Benzamide derivatives as modulators of 11beta-HSD1 for treating diabetes and obesity |
US8772296B2 (en) | 2006-06-08 | 2014-07-08 | Amgen Inc. | Benzamide derivatives and uses related thereto |
US7547697B2 (en) | 2006-07-05 | 2009-06-16 | Hoffmann-La Roche Inc. | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors |
WO2008003611A1 (en) * | 2006-07-05 | 2008-01-10 | F. Hoffmann-La Roche Ag | Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1) |
KR101089012B1 (ko) | 2006-07-05 | 2011-12-01 | 에프. 호프만-라 로슈 아게 | 11베타 하이드록시스테로이드 탈수소효소 유형 1(11β-HSD1)의 저해제로서의 알킬-피리다진 유도체 |
CN101484428B (zh) * | 2006-07-05 | 2011-11-16 | 霍夫曼-拉罗奇有限公司 | 作为1型11β羟基类固醇脱氢酶(11b-HSD1)抑制剂的烷基哒嗪衍生物 |
JP2009541434A (ja) * | 2006-07-05 | 2009-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型(11β−HSD1)の阻害剤としてのアルキルピリダジン誘導体 |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8299054B2 (en) | 2006-08-24 | 2012-10-30 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
WO2008053194A2 (en) * | 2006-11-03 | 2008-05-08 | Astrazeneca Ab | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
US7964618B2 (en) | 2006-11-03 | 2011-06-21 | Astrazeneca Ab | Chemical compounds |
US8673938B2 (en) | 2006-11-03 | 2014-03-18 | Astrazeneca Ab | Chemical compounds |
JP2010508338A (ja) * | 2006-11-03 | 2010-03-18 | アストラゼネカ アクチボラグ | 化合物 |
WO2008053194A3 (en) * | 2006-11-03 | 2008-10-02 | Astrazeneca Ab | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
EP2233480A1 (en) * | 2006-11-03 | 2010-09-29 | AstraZeneca AB | Chemical compounds |
DE102006058207A1 (de) * | 2006-12-11 | 2008-06-19 | Universitätsklinikum Schleswig-Holstein | Verfahren zur Herstellung spezifischer Inhibitoren der 11beta-Hydroxysteroid-Dehydrogenase Typ 1 mit Nor-Oleanan- oder Nor-Ursan-Grundgerüsten |
WO2008074384A1 (en) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS |
US8012955B2 (en) | 2006-12-28 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
US8697727B2 (en) | 2006-12-28 | 2014-04-15 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
US9181220B2 (en) | 2006-12-28 | 2015-11-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
DE102007005045A1 (de) | 2007-01-26 | 2008-08-07 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7816391B2 (en) | 2007-02-12 | 2010-10-19 | Astrazeneca Ab | Chemical compounds |
US8344016B2 (en) | 2007-02-12 | 2013-01-01 | Astrazeneca Ab | Pyrazole derivatives as 11-beta-HSD1 inhibitors |
US8093265B2 (en) | 2007-03-09 | 2012-01-10 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
US9371323B2 (en) | 2007-06-21 | 2016-06-21 | Incyte Holdings Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
EP2918586A1 (en) | 2007-06-21 | 2015-09-16 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
US9006260B2 (en) | 2007-06-21 | 2015-04-14 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
US8278318B2 (en) | 2007-06-21 | 2012-10-02 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
WO2008157752A1 (en) | 2007-06-21 | 2008-12-24 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
US9873698B2 (en) | 2007-06-21 | 2018-01-23 | Incyte Holdings Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
EP2540723A1 (en) | 2007-06-21 | 2013-01-02 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8541444B2 (en) | 2007-10-01 | 2013-09-24 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
US8372840B2 (en) | 2008-08-29 | 2013-02-12 | Xention Limited | Potassium channel blockers |
US8258138B2 (en) | 2008-08-29 | 2012-09-04 | Xention Limited | Potassium channel blockers |
US8673901B2 (en) | 2008-08-29 | 2014-03-18 | Xention Limited | Potassium channel blockers |
US9073834B2 (en) | 2008-08-29 | 2015-07-07 | Xention Limited | Potassium channel blockers |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8969382B2 (en) | 2008-10-23 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8785640B2 (en) | 2008-10-23 | 2014-07-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8598205B2 (en) | 2008-10-23 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8604203B2 (en) | 2008-10-23 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8927549B2 (en) | 2008-11-21 | 2015-01-06 | High Point Pharmaceuticals, Llc | Adamantyl benzamide derivatives |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US8741899B2 (en) | 2009-01-15 | 2014-06-03 | Abbvie Inc. | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof |
US8404719B2 (en) | 2009-01-15 | 2013-03-26 | Abbvie Inc. | Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers |
US8101614B2 (en) | 2009-01-15 | 2012-01-24 | Abbott Laboratories | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers |
WO2010083264A1 (en) * | 2009-01-15 | 2010-07-22 | Abbott Laboratories | Novel benzenesulfonamides as calcium channel blockers |
US8524894B2 (en) | 2009-06-04 | 2013-09-03 | Laboratorios Salvat, S.A. | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 |
US8426442B2 (en) | 2009-06-04 | 2013-04-23 | Xention Ltd | Compounds |
US8399481B2 (en) | 2009-06-04 | 2013-03-19 | Xention Ltd | Compounds |
WO2010139967A1 (en) | 2009-06-04 | 2010-12-09 | Xention Limited | Dihydroindole and tetrahydroisoquinoline derivatives useful as potassium channel inhibitors |
WO2010139953A1 (en) | 2009-06-04 | 2010-12-09 | Xention Limited | Compounds |
US8822452B2 (en) | 2009-06-04 | 2014-09-02 | Laboratorios Salvat, S.A. | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012134233A2 (ko) | 2011-03-31 | 2012-10-04 | 한국화학연구원 | 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 |
US9073906B2 (en) | 2011-03-31 | 2015-07-07 | Korea Research Institute Of Chemical Technology | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
AU2018203354B2 (en) * | 2011-12-21 | 2019-12-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9073864B2 (en) | 2012-03-29 | 2015-07-07 | Takeda Pharmaceutical Company Limted | Aromatic ring compound |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10323034B2 (en) | 2013-11-25 | 2019-06-18 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10047082B2 (en) | 2013-11-25 | 2018-08-14 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US11370789B2 (en) | 2013-11-25 | 2022-06-28 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US11560379B2 (en) | 2013-11-25 | 2023-01-24 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10787449B2 (en) | 2013-11-25 | 2020-09-29 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10047085B2 (en) | 2014-02-03 | 2018-08-14 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11535614B2 (en) | 2014-02-03 | 2022-12-27 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10399976B2 (en) | 2014-02-03 | 2019-09-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10807980B2 (en) | 2014-02-03 | 2020-10-20 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9624217B2 (en) | 2014-02-03 | 2017-04-18 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10087184B2 (en) | 2014-10-14 | 2018-10-02 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of RORγ |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11001583B2 (en) | 2014-11-05 | 2021-05-11 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10787745B2 (en) | 2014-12-05 | 2020-09-29 | Schlumberger Technology Corporation | Corrosion inhibition |
US10239838B2 (en) | 2014-12-19 | 2019-03-26 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
WO2016095205A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
US10829448B2 (en) | 2015-08-05 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Substituted benzoimidazoles as modulators of ROR-γ |
EP3365477A4 (en) * | 2015-10-19 | 2019-10-16 | Services Petroliers Schlumberger | INHIBITION OF CORROSION |
US10982337B2 (en) | 2015-10-19 | 2021-04-20 | Schlumberger Technology Corporation | Corrosion inhibition |
WO2017070026A1 (en) | 2015-10-19 | 2017-04-27 | Schlumberger Technology Corporation | Corrosion inhibition |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11357781B2 (en) | 2016-06-23 | 2022-06-14 | University Of Maryland, Baltimore | Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
US11911392B2 (en) | 2016-06-23 | 2024-02-27 | University Of Maryland, Baltimore | Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
US11911393B2 (en) | 2016-06-23 | 2024-02-27 | University Of Maryland, Baltimore | Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
US10759749B2 (en) | 2016-08-31 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic agent for diabetes |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10889593B2 (en) | 2016-12-21 | 2021-01-12 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10336771B2 (en) | 2016-12-21 | 2019-07-02 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US11345714B2 (en) | 2016-12-21 | 2022-05-31 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
US11718595B2 (en) | 2018-12-07 | 2023-08-08 | University Of Maryland, Baltimore | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors |
US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11590113B2 (en) | 2019-02-22 | 2023-02-28 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11058670B2 (en) | 2019-02-22 | 2021-07-13 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11684612B2 (en) | 2019-02-22 | 2023-06-27 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
WO2021159015A1 (en) * | 2020-02-07 | 2021-08-12 | Cytokinetics, Inc. | Nampt modulators |
WO2021236449A1 (en) * | 2020-05-18 | 2021-11-25 | Gen1E Lifesciences Inc. | P38alpha mitogen-activated protein kinase inhibitors |
US11286260B2 (en) | 2020-05-18 | 2022-03-29 | Gen1E Lifesciences Inc. | P38α mitogen-activated protein kinase inhibitors |
US11440918B2 (en) | 2020-05-18 | 2022-09-13 | Gen1E Lifesciences Inc. | p38α mitogen-activated protein kinase inhibitors |
US11926635B2 (en) | 2020-05-18 | 2024-03-12 | Gen1E Lifesciences Inc. | P38α mitogen-activated protein kinase inhibitors |
US11390581B2 (en) | 2020-10-29 | 2022-07-19 | Gen1E Lifesciences Inc. | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
US11555020B2 (en) | 2021-03-23 | 2023-01-17 | Gen1E Lifesciences Inc. | Substituted naphthyl p38α mitogen-activated protein kinase inhibitors |
US11976049B2 (en) | 2021-03-23 | 2024-05-07 | Gen1E Lifesciences Inc. | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
PE20041040A1 (es) | 2005-02-08 |
BRPI0406938A (pt) | 2006-01-03 |
JP2006517199A (ja) | 2006-07-20 |
CN100586927C (zh) | 2010-02-03 |
AR043355A1 (es) | 2005-07-27 |
CA2513349A1 (en) | 2004-08-05 |
US20060205772A1 (en) | 2006-09-14 |
TW200503994A (en) | 2005-02-01 |
CN1741986A (zh) | 2006-03-01 |
EP1590319A1 (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004065351A1 (en) | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | |
EP1448523B1 (en) | Heterocyclic compounds and methods of use | |
EP1638963B1 (en) | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors | |
AU2004255342C1 (en) | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | |
JP4700684B2 (ja) | 2型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体 | |
RU2228927C2 (ru) | Производные аминов или амидов, фармацевтическая композиция на их основе и способ антагонизирования рецептора y5 нейропептида npy | |
CA2570197C (en) | Nk1 antagonists | |
US7432281B2 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
WO2001019808A1 (en) | Chemical compounds and compositions and their use as cathepsin s inhibitors | |
MX2007008078A (es) | Compuestos organicos. | |
KR20010105394A (ko) | 디아릴 유도체 및 그의 의약으로서의 용도 | |
AU2005318392A1 (en) | Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin | |
EP1689712B1 (en) | 4-phenylpiperidine derivatives as renin inhibitors | |
US8552033B2 (en) | Inhibitors of CXCR2 | |
US7307095B2 (en) | Inhibitors of cathepsin S | |
US5025033A (en) | Alkylene diamines | |
Leclerc et al. | Synthesis and structure–activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands | |
JP2009500350A (ja) | 肥満症及び関連障害の治療用の新規アミノ酸誘導体 | |
KR20140085470A (ko) | 바닐로이드 수용체 리간드로서의 아민 치환된 메탄설폰아미드 유도체 | |
BRPI0711966A2 (pt) | compostos de pirrolidina como inibidores de renina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004704554 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2513349 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048025408 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006500009 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10542759 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004704554 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0406938 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10542759 Country of ref document: US |